Jérôme Berger announced as strategy and finance executive at Vect-Horus
January 28, 2025appointment, private biotechnology company
Vect-Horus, a private biotechnology company specialising in molecular development, has announced the appointment of Jérôme Berger to its board of …
Research collaboration announced between Oxford University and GSK
January 27, 2025Research and Development Cancer, Oncology, Oxford University, neoantigens, partnership, research and development
The GSK-Oxford Cancer Immuno-Prevention Programme was announced at the end of January and will focus on researching the prevention of …
Pharmapack Award Winners 2025 redefining pharmaceutical packaging and drug delivery
January 23, 2025Paris, Pharmapack 2025, Winners, pharmaceutical packaging and drug delivery
Award winners by category DELIVERY AND DEVICE INNOVATION SHL Medical for Elexy™ reusable electromechanical autoinjector ECO-DESIGN WINNER Huhtamaki for Omnilock™ …
Combination first-in-line treatment approved for patients with non-small cell lung cancer
January 23, 2025Research and Development J&J Innovative Medicine, Oncology, approval, non-small cell lung cancer
Johnson & Johnson Innovative Medicine have announced that the European Commission (EC) has approved a marketing authorisation for the combination …
Pharmapack Europe the ‘Heart of Pharma’ Start-ups in Paris
January 23, 2025Medical Communications, Public Relations Heart of Pharma, Paris, pharmapack
Six start-ups bestowed with new ‘heart of pharma’ commendation in recognition of innovations advancing drug delivery and packaging 22 January …
Biomarkers used in trial to prevent systematic onset of Crohns Disease before it begins in Europe-first project
January 22, 2025Research and Development Crohns Disease, Crohsn, Gastrointestinal tract, Takeda, biomarkers, ibd, project
Takeda, a global biopharmaceutical company, is due to launch a project, INTERCEPT, which will use biomarkers to prevent symptomatic onset …
First patients treated with HEMGENIX® (etranacogene dezaparvovec) gene therapy for haemophilia B in Denmark
January 21, 2025Sales and Marketing CSL, Denmark, genetic, haemophilia, treatment
21 January 2025 – Copenhagen, Denmark – CSL Behring Denmark today announced that the first Danish patients with haemophilia B …
Uniphar appoints new global head of Scientific Communications
January 17, 2025UniPhar, appointment
Global partner to pharma, medtech and biotech companies Uniphar has announced the appointment of industry leader Isaac Batley as its …
Pharmapack Predictions 2025: the Good the Bad and…. the Donald 2.0
January 17, 2025CPhI, Pharmpack, biologics, predictions
Biologic approvals, drug delivery advancements, GLP-1 generics and the long-sought funding return to drive a record year in 2025 13 …
David Loose appointed CEO of Essex Management
January 17, 2025David Loose has been appointed as chief executive officer of Essex Management, part of contract research organisation Emmes Group. After …
Dr Joerg Moeller appointed CEO of Antag Therapeutics
January 14, 2025Corporate
Novel obesity treatment-focused biopharmaceutical company Antag Therapeutics has announced the appointment of Joerg Moeller MD PhD as chief executive officer. …
Switzerland’s Basel Region Crowned ‘Europe’s Top Destination to Launch a Drug Device Company’, According to Pharmapack Report
January 14, 2025Switzerland, pharmapack, report
Pharmapack Europe: ‘Basel the best location for drug device innovation in Europe thanks to combination of world class manufacturing and …
University of Sheffield trial highlights immunotherapy-related improved survival rates for bladder cancer patients
January 14, 2025Research and Development Endocrinology, Oncology, Sheffield, astranzeneca, bladder cancer, immunotherapy, patients
The University of Sheffield, UK, have announced study results for its trial into the survival rates of patients with operable …
AnaCardio raises $19m in funding round for heart failure candidate
January 10, 2025Research and Development AnaCardio, Cardiology, cardiology, funding, heart failure
Swedish biopharmaceutical company AnaCardio has announced the completion of a Series A extension financing round that has raised $19m for …
IDDI announces two new appointments to its leadership team
January 9, 2025IDDI, appointment, leadership
The International Drug Development Institute (IDDI) has announced changes to its executive leadership team to strengthen the company’s leadership and …
University of Southern Denmark pairs with Argobio to launch next-generation RNA company Inverna Therapeutics
January 7, 2025Research and Development Argobio, Huntingdon's Disease, Inverna therapeutics, Neurology, RNA therapeutics, University of Southern Denmark ], gene splicing
The launch of new RNA company Inverna Therapeutics was announced today. Inerva Therapeutics begins with a programme aimed at transforming …
NMD Pharma’s Charcot-Marie-Tooth disease treatment granted ODD by FDA
January 6, 2025CMT, FDA, NMD Pharma, Orphan Drugs, Pain, nervous system, research and development
Biotech company NMD Pharma has announced that the US Food and Drug Association (FDA) have granted its Charcot-Marie-Tooth (CMT) disease …
NDA in China receives priority review status for lung cancer treatment
January 3, 2025Research and Development China, China National Medical products Administration, HUTCHMED, NDA, Oncology, epidermal growth factor receptor, non-small cell lung cancer, priority review
HUTCHMED have announced that the China National Medical Products Administration (NMPA) have granted a priority review for a new drug …
NICE recommendation for KORSERDU®▼ (elacestrant) marks ‘step-change’ in the treatment of ESR1-mutated metastatic breast cancer
December 19, 2024ESR1, Menari Group, NICE, breast cancer, drug
Elacestrant is the first tailored treatment for certain people with oestrogen receptor (ER)-positive HER2-negative locally advanced and metastatic breast cancer …
MHRA Grants Marketing Authorisation for LEO Pharma’s Anzupgo® ▼(delgocitinib) cream in Great Britain
December 16, 2024LEO Pharma, eczema
The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation in Great Britain for Anzupgo® (delgocitinib) 20mg/g cream …
Latest content
MHRA approves Romvimza for tenosynovial giant cell tumour
Panthera opens clinical trial site at Keele University
Santen joins inaugural Global Summit for Eye Health as partner
